ZeroStack (ZSTK) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
8 Jan, 2026Company overview and business model
Rebranding as ZeroStack, focusing on AI infrastructure via strategic ownership in OG Tokens, a blockchain enabling decentralized AI applications.
Operates global pharmaceutical distribution through Phatebo, with principal operations in Germany and sales across 28 countries.
Divested legacy hemp and cannabis business in September 2025 to focus on digital assets and pharmaceuticals.
Financial performance and metrics
As of January 2, 2026, 1,045,604 common shares were issued and outstanding.
Net proceeds from May 2025 Private Placement were $1.1 million; Cash Private Placement netted $13.66 million.
Received 71,766,135 OG Tokens (valued at $215.3 million) and 50,000,000 OG Tokens from private placements.
Use of proceeds and capital allocation
Proceeds from private placements allocated to digital asset treasury strategy, primarily OG Tokens, and to enhance AI business functionality.
Additional funds used for general corporate and working capital purposes.
Proceeds from May 2025 Private Placement used to purchase Solana, Ethereum, Sui, Ripple, and for corporate purposes.
Latest events from ZeroStack
- Net loss surged to $119.7M on digital asset losses as the company pivoted to an AI-focused treasury model.ZSTK
Q4 202527 Feb 2026 - Net loss narrowed to $2.7M as revenue fell and global expansion, cost cuts, and new launches continued.ZSTK
Q2 20242 Feb 2026 - Q3 revenue dropped and net loss widened, but U.S. and German growth prospects remain.ZSTK
Q3 202414 Jan 2026 - Registering 3.86M shares for resale; proceeds go to investors, not the company.ZSTK
Registration Filing16 Dec 2025 - 3.2 million shares registered for resale after acquisition and executive grants; no proceeds to issuer.ZSTK
Registration Filing16 Dec 2025 - 3.2 million shares registered for resale; no proceeds to company; global cannabis expansion focus.ZSTK
Registration Filing16 Dec 2025 - Shareholders to vote on TruHC acquisition, equity plan, and executive awards amid ongoing losses.ZSTK
Proxy Filing2 Dec 2025 - Proxy seeks approval for director elections, equity plan, executive SARs, and TruHC share issuance.ZSTK
Proxy Filing2 Dec 2025 - Key votes include director elections, share consolidation, and expanded equity incentives.ZSTK
Proxy Filing2 Dec 2025